We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Nonradioactive Serotonin Release Assay Compared to Gold Standard

By LabMedica International staff writers
Posted on 01 Feb 2016
Print article
The JANUS Automated Liquid Handling Workstation
The JANUS Automated Liquid Handling Workstation (Photo courtesy of Perkin Elmer)
The serotonin release assay (SRA) is considered the gold standard laboratory test for heparin-induced thrombocytopenia (HIT) and the classical SRA method uses platelets loaded with radiolabeled serotonin to evaluate platelet activation by HIT immune complexes.

Laboratory tests for HIT consist of immunoassays, usually enzyme-linked immunosorbent assays (ELISAs), and functional platelet activation assays. Immunoassays detect the presence of immunoglobulins that bind heparin: PF4 complexes, while functional tests detect platelet activation by immune complexes consisting of macromolecular aggregates of heparin: PF4 and antibody.

Scientists at the ARUP Laboratories Institute (Salt Lake City, UT, USA) and their colleagues have validated the performance characteristics of a high-performance liquid chromatography (HPLC) SRA method. The team used serum samples stored frozen until the time of evaluation that had been submitted to their laboratory for HIT testing. Reagent platelets were obtained by collecting blood from healthy donors known to be reactive and with no history of HIT, platelet dysfunction, or current nonsteroidal anti-inflammatory drugs (NSAID) use.

Assay setup was automated on a JANUS liquid handling system (PerkinElmer, Waltham, MA, USA), although platelets were pipetted manually. Serotonin released from reagent platelets was quantitated (ng/mL) by HPLC on a gel permeation chromatography (GPC), size exclusion chromatography (SEC), 1260 instrument (Agilent Technologies; Santa Clara, CA, USA) with fluorescent detection (excitation 285 nm, emission 345 nm). Results were expressed as percentage release and classified as positive, negative, or indeterminate based on previously published cutoffs.

The serum samples from 250 subjects with suspected HIT were tested in the HPLC-SRA and with the radioactive method. Concordant classifications were observed in 230 samples (92%). Sera from 41 healthy individuals tested negative. Between-run imprecision studies showed standard deviation of less than 6% release for positive, weak positive and negative serum pools. Stability studies demonstrated stability after two freeze–thaw cycles or up to a week of refrigeration.

The authors concluded that the HPLC-SRA has robust performance characteristics, equivalent to the classic radioactive method, which has long been considered the gold standard assay for HIT. Results from nonradioactive SRA methods using novel serotonin detection methods provide equivalent information to radioactive methods for HIT diagnostic algorithms but avoid the laboratory complexities of working with radioactivity. The HPLC-SRA method has been optimized to accommodate the demands placed on our high-volume reference laboratory by use of an automated dilutor to perform many pipetting steps and laboratory-developed software to perform calculations. The study was published in the February 2016 issue of the International Journal of Laboratory Hematology.

Related Links:

ARUP Laboratories Institute 
Perkin Elmer 
Agilent Technologies 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.